

1 **Protocol for a cluster randomised controlled trial to evaluate the**
2 **effectiveness of digital health interventions in improving non-**
3 **communicable disease management during the pandemic in rural**
4 **Pakistan**

5 Xiaolin Wei,^{a,b} Nida Khan,^c Hammad Durrani,^b Naila Muzaffar,^c Victoria Haldane,^b John D. Walley,^d Kevin
6 Thorpe,^a Erjia Ge,^a Shiliang Ge,^a Warren Dodd,^e James Wallace,^e Garry Aslanyan,^{f,a} Audrey Laporte,^b
7 Muhammad Amir Khan,^c

8 ^a Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada

9 ^b. Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada

10 ^c. Association for Social Development, Islamabad, Pakistan

11 ^d. Nuffield Centre for International Health and Development, University of Leeds, Leeds, UK

12 ^e. School of Public Health Sciences, University of Waterloo, Waterloo, Canada

13 ^f. The Special Programme for Research & Training in Tropical Diseases, World Health Organization,
14 Geneva, Switzerland

15

16

17

18 Email addresses of authors

19 Xiaolin Wei, xiaolin.wei@utoronto.ca

20 Nida Khan, nidakhan@asd.com.pk

21 Hammad Durrani, hammad.durrani@mail.utoronto.ca

22 Naila Muzaffar, naila@asd.com.pk

23 John Walley, J.Walley@leeds.ac.uk

24 Kevin Thorpe, kevin.thorpe@utoronto.ca

25 Victoria Haldane, v.haldane@mail.utoronto.ca

26 Erjia Ge, erjia.ge@utoronto.ca

27 Shiliang Ge, sarah.ge@mail.utoronto.ca

28 Warren Dodd, wdodd@uwaterloo.ca

29 James Wallace, james.wallace@uwaterloo.ca

30 Garry Aslanyan, aslanyang@who.int

31 Muhammad Amir Khan, ccp@asd.com.pk

32

33 Corresponding:

34 Professor Xiaolin Wei, Dalla Lana School of Public Health, University of Toronto,

35 Email: xiaolin.wei@utoronto.ca

36 And Dr. Muhammad Amir Khan, Association for Social Development, Pakistan

37 Email: ccp@asd.com.pk

38 **Abstract**

39 **Background:** The COVID-19 pandemic has revealed gaps in global health systems,
40 especially in the low- and middle-income countries (LMICs). Evidence shows that
41 patients with non-communicable diseases (NCDs) are at higher risk of contracting
42 COVID-19 and suffering direct and indirect health consequences. Considering the future
43 challenges such as environmental disasters and pandemics to the LMICs health
44 systems, digital health interventions (DHI) are well poised to strengthen health care
45 resilience. This study aims to implement and evaluate a comprehensive package of
46 DHIs of integrated COVID-NCD care to manage NCDs in primary care facilities in rural
47 Pakistan.

48

49 **Methods**

50 The study is designed as a pragmatic, parallel two-arm, multi-centre, cluster
51 randomised controlled trial. We will randomise 30 primary care facilities in three districts
52 of Punjab, where basic hypertension and diabetes diagnosis and treatment is provided,
53 with a ratio of 1:1 between intervention and control. In each facility, we will recruit 50
54 patients who have uncontrolled hypertension. The intervention arm will receive training
55 on an integrated COVID-NCD guideline, and will use a smartphone app-based
56 telemedicine platform where patients can communicate with health providers and peer-
57 supporters, along with a remote training and supervision system. Usual care will be
58 provided in the control arm. Patients will be followed up for 10 months. Our primary
59 indicator is systolic blood pressure measured at 10 months. A process evaluation
60 guided by implementation science frameworks will be conducted to explore

61 implementation questions. A cost-effectiveness evaluation will be conducted to inform
62 future scale up in Pakistan and other LMICs.

63

64 **Discussion:**

65 Our study is one of the first randomised controlled trials to evaluate the effectiveness of
66 DHIs to manage NCDs to strengthen health system resilience in LMICs. We will also
67 evaluate the implementation process and cost-effectiveness to inform future scale-up in
68 similar resource constrained settings.

69

70 Word account: 292 (300 maximum)

71

72 **Trial registration:** ClinicalTrials.gov Identifier - NCT05699369

73

74 **Keywords:** Digital health interventions, non-communicable diseases, cluster
75 randomised trial, implementation science, resilience, Pakistan

76

77

78

79

80

81 **Introduction**

82 Throughout the COVID-19 pandemic, delivering care for non-communicable diseases (NCDs) has been
83 challenged, especially in low-and-middle-income countries (LMICs) with high burdens of NCDs such as
84 Pakistan (1). Indeed, Pakistan ranks 7th globally amongst countries with the highest number of persons
85 living with diabetes and hypertension (2). People with diabetes and hypertension require ongoing care
86 and contact with health providers. Yet in Pakistan, NCDs are inadequately managed in primary care, as
87 evidenced by high rates of vascular complications and low blood pressure control rates (<30%) (3,4). The
88 situation was made worse by the COVID-19 pandemic. Throughout COVID-19, accessing NCD care in
89 Pakistan was made more difficult due to infection control and social distancing measures at health
90 facilities (5). At the same time, people with these conditions are at greater risk of severe complications
91 and poor health outcomes from COVID-19, prompting some to forgo care seeking to avoid infection (6,7).

92
93 The NCD Countdown 2030 specifically calls for focused scale-up of feasible and cost-effective
94 interventions to ensure people living with NCDs can access the care they need, while supporting the dual
95 goal of helping countries build back better and creating a sustainable foundation for a more ambitious
96 global NCD agenda (8). Digital health interventions (DHIs), including telemedicine, mhealth, virtual care,
97 and remote management have been used prior to the pandemic to provide feasible and effective
98 integrated NCD care, especially in managing multimorbidity, delivering precision medicine, and increasing
99 medication adherence (9). Building upon these prior efforts, digital health tools have emerged during the
100 pandemic as an important strategy to improve health system resilience globally. A WHO rapid review
101 conducted in May 2020 found that half of the 163 countries reviewed had disrupted their NCD services
102 during the pandemic, and over half began to adopt DHIs such as telemedicine in their NCD services, with
103 various adoptions in the US, China, and Iran (10,11). The implementation of DHIs has largely been a
104 strategy to limit exposure to COVID-19 when seeking or providing care, reduce nosocomial and
105 community transmission, and has emerged as acceptable to both health providers and patients (6,12).
106 However, DHIs require robust information technology systems, privacy and security infrastructure, and
107 importantly, reliable internet or mobile phone coverage and connectivity. Most primary care facilities in
108 LMICs lack the capacity to develop qualified telemedicine platforms and ensure their ongoing availability

109 (13). Given these requirements and constraints, limited functions of DHI, such as phone calls and text
110 messages were reported as the most common form of DHIs, with fewer examples leveraging more
111 advanced features such as smartphone app-based operations mostly applied in developed countries
112 (14,15).

113
114 There are 185 million mobile connections in Pakistan among a total population of 225 million; and around
115 half of these connections are smart phone users (16). In Pakistan, provincial governments have made
116 efforts to support the development of DHIs. For instance, the Government of Sindh approved the
117 Telemedicine and TeleHealth Bill 2021, which aimed to facilitate, enhance and improve access to
118 healthcare through digital health platforms to ease the shortage of healthcare professionals (17). Pakistan
119 has seen several DHI initiatives piloted by provincial governments and not-for-profit organisations.
120 Telehealth clinics were established in some isolated and rural areas of Punjab, Sindh and Khyber-
121 Pakhtunkhwa provinces to provide easy access to healthcare specialties such as dermatology, radiology
122 and psychiatry (18–20). In a recent initiative, a tele-triage centre was established in Punjab with good
123 success, focused on management and follow-up COVID-19 patients (21). However, the initiatives are all
124 sporadic that there is no sustained design and plan to scale up DHIs at health system level in Pakistan.
125 For longer-term success, DHIs must consider culture, norms and traditions in Pakistan to improve
126 acceptability, and meet technical, procedural and operational needs (22).

127
128 Our previous studies in Pakistan demonstrated the feasibility and effectiveness of a community-based
129 case management programme for patients with hypertension or diabetes (23,24). Based on this, we aim
130 to design and implement a comprehensive package of DHI interventions to improve the management of
131 patients with NCDs (hypertension and diabetes in this setting) in rural primary care facilities in Punjab
132 Province, Pakistan during the pandemic. In addition, DHIs tested in this trial would strengthen the health
133 system resilience and help to prepare other hazards, such as environment related disasters of flood as
134 recently happened in Pakistan. We will also explore the implementation questions regarding feasibility
135 and cost-effectiveness of this comprehensive package of DHIs for future scale-up in Pakistan and other
136 LMICs to prepare all-purpose hazards.

137

138 **Material and Methods**

139 This protocol is reported according to the SPIRIT guidelines (25).

140 Study Design

141 We will conduct a parallel two-arm, multi-centre, cluster randomized controlled trial, using a 1:1 allocation
142 ratio, to evaluate whether the DHI package is superior to usual care for blood pressure management
143 among patients with NCDs. The study design is informed by the Medical Research Council framework
144 (26) on complex interventions and implementation science frameworks with an embedded theory-based
145 process evaluation to examine implementation questions regarding acceptability, reach, adoption,
146 implementation and maintenance, as well as appropriateness and burden of technology use (27,28). In
147 addition, we will conduct an incremental cost-effectiveness analysis to inform future scale-up. The trial
148 protocol has obtained ethical approval from the Office of Research Ethics at the University of Toronto
149 (Ref: 42337) and the Institutional Review Board of the Association for Social Development, Pakistan (Ref:
150 IORG0011016 dated 04 March 2022).

151

152 Setting

153 We will implement the study in rural Punjab, Pakistan. The Province of Punjab, Pakistan, has 110 million
154 inhabitants in 36 districts. About two-third of the population live in rural areas and experience challenges
155 in accessing health care such as physical distance, affordability, and social constraints for woman
156 travellers. In many situations, access challenges are further complicated by a low quality of care in NCD
157 diagnosis and treatment (29). In Punjab, the rural population is served mainly by a network of public
158 health and primary care facilities consisting of more than 315 Rural Health Centres (RHC) and 120
159 District Hospitals. Each RHC serves a catchment population of approximately 150,000 – 250,000 rural
160 inhabitants. These RHCs offer NCD diagnostic and treatment services, emergency obstetric and neonatal
161 care, and treatment of general ailments such as malnutrition and arthritis. The RHC staff include at least:
162 1) three or more doctors; 2) a range of allied health workers including drug-dispensers, lady health
163 visitors, nurses, and laboratory technicians; and c) support staff such as record clerks, store-keepers,
164 office support staff, and cleaners. The Association for Social Development (ASD), a non-government

165 organisation (NGO) and the local project lead, is leading a project funded by the World Diabetes
166 Foundation (WDF) which has introduced diagnosis, treatment, and follow-up care for diabetes and
167 hypertension in 84 RHCs in Punjab. RHCs provide outpatient services from 8am to 2pm during weekdays
168 with emergency services available 24 hours a day. Patients who visit RHCs are mostly poor and prefer to
169 use public health service because it is free of charge. Often, they do not use private consultations.

170

171 Randomization and blinding:

172 We will recruit and randomise 30 RHCs in three districts: Sarghoda, Jhang and Muzaffargarh, in rural
173 Punjab. All three districts are a part of the WDF project which has already provided diagnosis and
174 treatment care for hypertension and diabetes. RHCs will be stratified by district and further balanced on
175 population using covariate constrained randomisation, and allocated into intervention and control at 1:1
176 ratio (30). With covariate constrained randomisation, many possible allocation plans are constructed. For
177 each plan a balance score is calculated that represents the degree of balance on the covariates of
178 interest. The final randomisation scheme is then randomly selected from the collection of plans with
179 acceptable balance. In this case, it is selected from the top 500 plans with least imbalance on population.
180 RHCs will not be blinded due to the nature of the intervention. To mitigate the risk of bias, we will: 1) mask
181 the statistician team when data is presented and analysed; and 2) employ objective outcomes.

182

183 Eligibility and recruitment

184 Eligible participants are patients who 1) are aged 25 years or older; 2) reside in the catchment of selected
185 RHCs, 3) provide informed consent, 4) are newly diagnosed of hypertension, i.e., having a baseline blood
186 pressure reading (recorded from the second blood pressure reading using a validated electronic blood
187 pressure machine) of more than 140/90 mmHg; or who is an existing hypertensive patient but with
188 uncontrolled blood pressure with a baseline blood pressure over 140/90 mmHg, and 5) have a
189 smartphone or can access to a smartphone from a relative. Exclusion criteria include having an acute
190 cardiovascular event in the last three months, terminal disease, or other conditions that the RHC staff
191 determine impossible to participate. We will recruit patients into the studies via allied health workers who
192 will screen patients for eligibility during their visit to RHCs, explain the study purpose, and obtain oral

193 informed consent. Based on the NCD patient data reported from the RHCs, on average, 25-30
194 hypertensive patients are enrolled at a single RHC each month, we estimate that the recruitment will take
195 two months when recruiting both new and existing patients. In total 1500 patients will be enrolled in the
196 study. Sample size calculations are explained below.

197

198 **Procedures**

199 Control arm

200 Our control arm will implement usual care, which is the routine hypertension and diabetes diagnosis and
201 treatment under the WDF project. The WDF project provides initial Zoom-based training of NCD care to
202 RHC staff, but no tele-mentorship is offered. Currently, NCD care is delivered through outpatient
203 consultations where patients must visit RHCs to get screened, diagnosed, registered, and treated. RHCs
204 stopped service from April to June 2020 due to the pandemic, but since August 2020, regular visits to
205 RHCs have been largely resumed. Basic anti-hypertensive and anti-diabetic medicines including insulins
206 are provided free of charge in RHCs. In case of shortage, patients are advised to come back or purchase
207 from private pharmacies. Patients are referred to district hospitals for cardiovascular disease or COVID-
208 19 diagnosis if suspected. Under the usual care, patients with hypertension or diabetes are required to
209 visit RHCs every month to renew their medications and measure their blood pressure. No other
210 interventional components will be implemented in the control arm.

211

212 Intervention arm

213 We will implement a comprehensive package of DHIs to connect patients, patient champions and public
214 health providers to improve management of NCDs during the pandemic, including 1) providing training to
215 health providers regarding an integrated NCD-COVID guideline; 2) using a smartphone app to improve
216 NCD case management and linking with patient champions; and 3) employing tele-mentoring platform to
217 improve quality of care (Fig 1). Patient champions are experienced patients who can provide peer
218 support, which has been used by ASD in its tuberculosis project. DHIs in the above three categories are
219 described in full below and then summarised according to the WHO classification of DHI categories as 1.0
220 (client/ patient) and 2.0 (health providers) for cross-reference (31).

221 **Fig 1** Diagram of intervention activities

222 *Integrated COVID-NCD guideline*

223 We have developed an integrated COVID-NCD guideline to support RHC staff to deliver care to patients
224 with flu-like symptoms (for symptomatic SARS-COVID-2 and other influenza viruses) in terms of
225 promoting rational use of personal protection equipment (PPE), promoting COVID-19 vaccination, and
226 providing case management, health education, and home quarantine support. This guide is based on our
227 previous experience in developing COVID-19 guidelines for primary healthcare facilities in Asia and Africa
228 (32,33). The guideline integrates with existing hypertension and diabetes management guideline in
229 Punjab. We also developed two versions of guidelines and training modules, one for the doctor and one
230 for the allied health workers (WHO DHI 2.8) in RHCs. The training materials for allied health workers
231 focus on using a smartphone app to improve patient retention to care, adherence to medications and
232 healthy lifestyles such as reducing sugar intake, physical activity, and smoking cessation in local context
233 (WHO DHI 2.2 and 2.4).

234

235 *A smartphone app*

236 We developed a smartphone app to link patients with RHC staff and patient champions. The app is an
237 adaptation of OneImpact currently employed to provide management for patients with drug resistant
238 tuberculosis in Pakistan. Patients will be provided the option of visiting RHCs every two months with
239 prolonged prescriptions. Patients will be able to use the app to a) access knowledge on NCD and
240 COVID-19/ flu care, including medication adherence and healthy lifestyle for managing hypertension and
241 diabetes at home, and knowledge to prevent COVID-19 transmission, home management, infection
242 control and when to seek health advice (WHO DHI 1.1); b) report any medical issues to allied health
243 workers in RHCs (WHO DHI 1.5); c) receive virtual care (i.e., reminders and consultation calls) from allied
244 health workers in RHCs based on their medical issues (WHO DHI 1.1, 2.2 and 2.4); d) if not responding to
245 reminders nor reporting any medical issues, patient will receive follow-up calls from allied health workers
246 during the gap month (WHO DHI 1.1, 2.2 and 2.4); e) participate in quarterly patient-health provider
247 forums (WHO DHI 1.6); and f) participate monthly in peer-support sessions with patient champions for

248 practicing recommended healthy behaviours, and addressing social issues in adherence to treatment and
249 access to hospital and stigma (WHO DHI 1.3).

250

251 *Tele-mentoring*

252 We will conduct tele-mentoring provided by specialists in District Hospitals, based on the Extension for
253 Community Healthcare Outcomes (ECHO), a remote training and mentoring system with proved effective
254 to improve NCD management (34). We will employ the ECHO case-based learning approach using best
255 practice and data within RHCs regarding NCD management, COVID-19 screening, prevention, and home
256 management (WHO DHI 2.5 and 3.1).

257

258 Upon recruitment, patients in the intervention arm will be facilitated by an allied health worker on site
259 regarding how to install and use the app. For patients who do not have access to a smart phone, or who
260 have low smartphone literacy, one of their family members who has a smartphone or good smartphone
261 literacy will be trained either on site or within a week of enrolment. We will identify “patient champions”
262 who are persons with lived experience of well managed diabetes or hypertension in the catchment area
263 and are willing to provide consultation support. We will have one male and one female patient champion
264 in each district. Creation of study materials and intervention components will be grounded in a gender and
265 culturally responsive approach, informed by local stakeholders and best practices, to support equitable
266 delivery of services and workforce capacity building.

267

268 **Outcomes**

269 The primary outcome is systolic blood pressure at 10 months measured in the RHC. Systolic blood
270 pressure has been commonly used to measure hypertension management outcomes(35). It is also an
271 important indicator in managing patients with diabetes (36,37). High blood pressure alone is a significant
272 risk for cardiovascular disease(38). Our secondary outcomes include NCD related indicators such as: 1)
273 diastolic blood pressure (mmHg) measured in the RHC at 10 months; 2) percentage of patients with
274 controlled blood pressure measured below 140/90 mmHg for patients with hypertension but without
275 diabetes, and below 130/80 mmHg for patients with diabetes at 10 months; 3) random blood glucose at

276 10 months (mmol/L); 4) body mass index (BMI) at 10 months; 5) number of consultations with RHC
277 doctors, including both in-person and virtual consultations; 6) systolic and diastolic blood pressure
278 measured at 6 months. We will also measure indicators related with COVID-19 including: 7) proportion of
279 patients who have had at least three doses of COVID vaccinations; 8) proportion of participants been
280 admitted to district hospitals for any reasons; 9) all-cause mortality rate during the 10 months. We are not
281 able to measure better recognisable indicators for diabetes management such as haemoglobin A1c
282 because the test is not available in RHCs and is costly.

283

284 **Sample size**

285 Sample size is based on demonstrating the intervention improves systolic blood pressure. A difference of
286 3 mmHg in systolic blood pressure at the population level is deemed to be the minimal clinically important
287 difference to detect. Due to the pragmatic nature of this trial, which tends to attenuate treatment effects, a
288 difference of 3 mmHg in this setting indicates an effective treatment (39). Based on prior work the
289 standard deviation of systolic blood pressure is expected to be about 11 mmHg (40,41). We will further
290 assume a modest intra-class correlation of 0.03 and set a Type I error probability of 0.05 and plan on 40
291 patients per cluster for the sample size estimation. Sample size calculations for the comparison of means
292 in cluster trials indicate that 524 patients per group would be required for 85% power and 614 patients per
293 group would be required for 90% power. Although 614 is slightly higher than the 600 expected from 15
294 clusters of 40 each, the adjustment of baseline systolic blood pressure in the analysis will increase the
295 power relative to the simple unadjusted analysis reflected in the sample size estimation. Considering a
296 20% loss-to-follow-up rate based on our previous trials in Pakistan and China we aim to increase to 50
297 patients per cluster, that is a total of 1500 patients to be recruited (23,42). We do not anticipate loss-to-
298 follow-up at the cluster level. Power will increase if all clusters meet the enrolment target of 50 patients.

299

300 **Internal pilot process**

301 We will assess the feasibility of implementing the intervention and running our trial processes during an
302 internal pilot study that will be conducted after the randomisation but before the main trial. The pilot
303 intervention will be conducted in one RHC of the intervention arm and one RHC in the control arm out of

304 the three selected districts. The internal pilot study aims to assess recruitment rates and the extent to
305 which the intervention is delivered within RHCs; it will also contribute outcome data to the main trial. In the
306 intervention RHC, we will pilot train RHC staff using the integrated COVID-NCD guideline and
307 demonstrate how to use the smartphone app for consultation and communication with patients. We will
308 recruit patients over the course of one week to test feasibility of recruitment. We will then follow up
309 patients for two weeks to understand if patients are able to use the app for health education and
310 communication with health providers. We will also train patient champions and conduct a peer support
311 session to test its feasibility. All intervention and data collection tools will be pilot tested and revised
312 based on feedback. In the control RHC, we will pilot the data collection tools, recruit patients over a week
313 and follow up for two weeks to understand recruitment and retention. The two RHCs in the pilot study will
314 be recruited and followed-up for one month, and the decision as to whether to continue with the full trial
315 will then be decided based on two key criteria: 1) sufficient levels of recruitment; 2) acceptability and
316 feasibility of interventions (at least 50% of health providers trained and 50% using the smartphone app
317 and integrated COVID-NCD guidelines at the end of the month). If these criteria are met, the internal pilot
318 RHCs and their outcome data will then become part of the main trial,

319

320 **Process evaluation**

321 Using the RE-AIM framework, we aim to describe the health system and service delivery context in which
322 the intervention is implemented, explore delivery and dose of intervention components received, and
323 understand mechanisms of impact and unanticipated consequences on health providers and parents
324 (43). Methods will include document review (e.g., meeting minutes, programme notes, record reviews
325 etc), training session observations, and qualitative interviews with stakeholders. Specifically, we aim to
326 understand: 1) Reach: the recruitment process and programme inclusion; 2) Effectiveness (feasibility and
327 acceptability): to what extent our measures are understood and accepted by patients; 3) Adaptation:
328 changes of interventions made at the facility level; how the NCD-COVID care connects with other
329 programmes such as tuberculosis and immunisation; and any resistance from structural, professional or
330 personal factors in adopting the change; 4) Implementation: issues related to fidelity/quality of
331 implementing the NCD-COVID programme, and any unanticipated consequences; 5) Maintenance: to

332 what extent the NCD-COVID programme is institutionalized in different RHCs. Our previous similar work
333 will inform this evaluation (44–46). Detailed methods for sampling, data collection and analysis will be
334 produced later following local consultations with the intention of balancing methodological rigor with an
335 approach responsive to gender and equity. The data will be analysed using a thematic approach reported
336 based on Consolidated Criteria for Reporting Qualitative Studies (COREQ) (47,48).

337

338 **Cost-effective analysis:**

339 An incremental cost effectiveness analysis will be conducted to estimate the added benefits of the
340 intervention regarding extra reduction of 1 mmHg patient systolic blood pressure in the intervention arm
341 compared with that in the usual care from a societal perspective, which entails an assessment of all
342 resource costs irrespective of payer. Costs associated with intervention over and above usual care
343 (excluding research costs) will be collected and used together with the above effectiveness/outcome
344 measures to calculate the incremental cost-effectiveness ratio(48). Costs will include capital costs such
345 as training, other costs to strengthen the capacity of providers to deliver enhanced services, and recurrent
346 costs such as drugs and laboratory tests. Salaries of staff in RHCs will be included in case of extra
347 working time is sought in some clusters during the intervention. Project logbook review and interviews
348 with managers will be conducted to obtain cost data. Hospitalisation and consultation costs for any
349 medical reasons during the trial period, including travel and waiting time, of patients and their relatives will
350 be recorded and converted into monetary forms using conventional age-sex adjusted market wages. We
351 will use net benefit regression framework which will allow us to adjust for potential confounders and to
352 calculate the clustered standard errors using the sandwich variance estimators to account for a clustered
353 randomised design (49). Markov models will be used to simulate possible future states of the intervention,
354 and to capture possible longer-term health outcomes (e.g., additional years of life) and associated costs
355 of care (50).

356

357 **Data collection**

358 We will measure patient blood pressures, random blood glucose, and patient body weight and height at
359 randomisation and during each in-person consultation at RHC. We will remind patient to visit RHCs for

360 the last measure at 10 months. During each consultation, the RHC doctor will measure participants' blood
361 pressure using a calibrated and standardised electronic sphygmomanometer after five minutes of seated
362 rest for two times with an interval of two minutes. If the difference in the two consecutive readings is over
363 5 mmHg, a third measure will be taken. The lower readings in systolic blood pressure of the last two
364 measures, together with the diastolic blood pressure measured with the determining systolic blood
365 pressure, will be recorded as patient blood pressure. Doctors will also measure body weight and height
366 using standardised scales. Blood samples will be collected and analysed in RHC according to national
367 guidelines for random plasma glucose. We will record all biomedical indicators on a revised treatment
368 card that is routinely used in RHCs, including patient basic demographics, smoking status, COVID-19 and
369 NCD diagnosis (including hypertension, diabetes, chronic obstructive pulmonary disease, cancer, and
370 cardiovascular disease), consultation dates (including both physical and virtual), and medication
371 prescriptions. We will conduct a questionnaire survey at 10 months by trained ASD staff to collect patient
372 socioeconomic status, disability condition, and costing data related with medical consultations, medicine,
373 laboratory tests and any hospitalisation, as well as any opportunity cost. Patients will be approached in
374 the community if not presented in RHCs after three reminders or loss-to-follow-up during the trial, and
375 post-posthumously with their close family members for patients who died during the trial. COVID-19
376 vaccination information will be collected from the National Vaccination Database.

377

378 Statistical analysis

379 We will present appropriate descriptive statistics for RHCs and at the individual level, along with
380 appropriate summary statistics and their associated 95% confidence intervals for all the outcomes. Then,
381 for all outcomes, we will produce a main set of estimates of intervention effectiveness using cluster-level
382 methods of analysis suitable for cluster trials. In particular, a linear mixed effect model will be used to
383 analyse the primary outcome (systolic blood pressure) adjusting for the baseline systolic blood pressure,
384 district (the stratification factor), and patient level factors (socioeconomic status, religious and disability).
385 For other continuous secondary outcomes a similar analysis will be employed. Binary secondary
386 outcomes will be analysed with the generalised estimating equation (GEE) approach, employing a
387 binomial family with logit link function and exchangeable working correlation structure on sites. There will

388 be no interim analyses. Intent to treat analysis will be conducted. An inverse probability weighted analysis
389 will be conducted in the event of significant loss to follow-up (more than 10%). A formal statistical analysis
390 plan will further describe the analysis, including any other pre-specified covariates to adjust for.

391

392 Analysis of process evaluation

393 Both quantitative and qualitative data will be analysed. The implementation data from the trial, including
394 program logbooks and app usability data, will be summarised, described and analysed using appropriate
395 statistical methods. The qualitative data will be collected using a descriptive approach where information
396 is gathered by interviewing those experiencing the phenomenon under investigation as part of a mixed
397 methods approach (51). Notes will be reviewed after each interview to identify emergent topics and allow
398 for exploration in subsequent interviews. Data will be translated and transcribed, then analysed using
399 NVivo 10. Qualitative data analysis will use a thematic approach to group information from the document
400 review and stakeholder interviews into themes guided by constructs in the RE-AIM framework.

401

402 Trial management

403 A data management committee will be established to 1) safeguard the safety and privacy of patients
404 involved, and to 2) ensure that all data are collected according to agreed ethical guidelines, properly
405 stored and only used for research purposes. A trial management unit (TMU) will be established in
406 Islamabad, Pakistan with a trial manager and one staff locally and a research coordinator from University
407 of Toronto. TMU will manage the day-to-day activities of the trial. Prof Xiaolin Wei from the University of
408 Toronto and Dr Muhammad Amir Khan from ASD will be the co-guarantors of the trial who have full
409 access to the trial dataset. Prof. Kevin Thorpe will be the lead statistician. A trial steering committee will
410 be established and led by external members. We will organise virtual trial steering committee meetings at
411 the beginning of the study, and then every six months. The committees may also meet on an ad hoc
412 basis should needs arise.

413

414 **Discussion**

415 To our knowledge, this trial is one of the first to evaluate the effectiveness of a comprehensive digital
416 health intervention package in improving NCD management and health system resilience in LMICs.
417 Ambitious action to tackle NCDs is crucial given that most LMICs are falling short of the targets set out in
418 Sustainable Development Goal 3.4 to reduce NCD mortality by a third between 2015 and 2030. The
419 pandemic has further derailed progress, both through the disproportionate impact of COVID-19 on people
420 with NCDs, as well as through the massive health systems and NCD care disruptions resulting from
421 COVID-19 response efforts. Similar disruptions of NCD care were seen in the recent floods. Not only
422 have these disruptions affected people already living with NCDs, but limited access to screening and
423 diagnostics during the pandemic means many more are undiagnosed and presenting to care with higher
424 acuity, complexity, and in need of comprehensive primary services.

425
426 Our interventions fit well into global calls, as well as local priorities in Punjab for implementing and scaling
427 up cost-effective digital solutions for NCD care in primary care settings (8,52). Based on this, we
428 developed the smartphone app based DHIs to improving patient-provider communication. The app was
429 adapted from one that has already been employed for managing MDR-TB patients in Pakistan. Through
430 the app, patients will receive integrated NCD-COVID care virtually, therefore reducing half of their routine
431 in-person visits to RHCs while getting more rapid feedback from RHC staff. We will also provide patient
432 peer support and patient provider communication on a regular basis. We will engage the NCD
433 programme at the national, provincial and district levels in developing guidelines and training modules to
434 ensure the materials are ready to be adapted to other remote areas and the project can be scaled up in
435 Pakistan. In addition, the trial is designed as a hybrid trial that will test both the evidence, the
436 comprehensive DHI package, and the implementation strategy, with an aim to facilitate future scale-up
437 other LMICs. We will employ the RE-AIM framework in our process evaluation and a cost-effectiveness
438 analysis to provide evidence on implementation, adaptation, maintenance and scalability of this DHI
439 package in similar resource constraint settings.

440
441 The study has several limitations. First, it is an open label trial where both health providers and patients
442 cannot be blinded, which will introduce biases on performance of both health providers and patients.

443 However, we will minimise any of the bias by collecting objective patient indicators using standardised
444 equipment purchased by the project. We will blank the allocations from the statisticians in data analysis.
445 Second, there is a risk of non-compliance of health providers and patients. We will provide on-site
446 supervision and the ECHO-based tele-mentoring with health providers to identify non-compliance and
447 provide timely feedback. Patient champions will connect patients or their relatives who have low literacy in
448 smartphones and who do not attend virtual consultations. In addition, we will provide gender sensitive
449 support in matching the patient champions and patients. Third, Pakistan is currently under a national
450 emergency of severe flooding. Though Punjab is largely not affected, it may cause shortage in staff and
451 funding for NCDs. Our interventions will help the public health system to strengthen their resilience to
452 respond to different disasters. We will document the context and any changes and continue to engage
453 with the provincial NCD program for possible way of mitigations.

454
455 In conclusion, we present the protocol of a pragmatic cluster randomised controlled trial to evaluate the
456 effectiveness of a comprehensive DHI package to improve management of NCD and improve resilience
457 in public primary care facilities in rural Punjab, Pakistan. The trial is co-designed with Pakistani NGO and
458 governmental stakeholders, in line with the WHO's framework on integrated people centred health
459 services to institutionalise DHIs to respond to health system challenges. If proved successful, we aim to
460 adapt and scale up the DHI package in rural Pakistan and other LMICs with similar challenges.

461

462 **Trial status and timelines**

463 The trial is registered at: [ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT05699369) (Identifier: NCT05699369)

464

465 **Timelines**

466 The study will be done over a 24-month period, with a nine-month preparation and pilot phase, a two-
467 month patient recruitment, 10 months month treatment phase for all patients, and a three-month data
468 analysis and write-up stage. We will disseminate trial results through research articles and policy briefs.

469 See Fig 2 for details of the trial timeline.

470 **Fig 2** Trial timelines

471

472 **List of abbreviations**

473 ASD: Association of Social Development

474 DHI: Digital Health Intervention

475 ECHO: Extension for Community Healthcare Outcomes

476 RHC: Rural Health Centre

477 NCD: Non-Communicable Diseases

478 LMICs: Low-and-Middle-Income Countries

479 TMU: Trial Management Unit

480 WDF: World Diabetes Foundation

481 WHO: World Health Organisation

482

483 **Contributors**

484 All authors made substantive contributions to the trial development and provided final approval for this
485 manuscript. XW, MAK, NK and JDW designed the trial and related studies. XW drafted the manuscript.

486 NK, NM, HD contributed to the pilot study. KT contributed to the statistical issues in the study design. JW,

487 NK, NM, HD, SG and GA contributed to trial intervention materials and critically reviewed the manuscript.

488 XW, VH and EG contributed to ethics development. WD and VH contributed to the qualitative study. JW

489 contributed to digital health intervention review. NK and AL contributed to the health economic evaluation.

490 XW and MAK are co-principal investigators of the trial.

491

492 **Acknowledgement:**

493 We thank the Steering Committee Members: Mr. Arif Muneer (Pakistan and the Chair of the Committee),

494 Dr. Haroon Jehangir (Former Directorate General of Health Punjab Pakistan), Dr. Shahzad Khan (Health

495 Services Academy Pakistan), Dr. Muhammad Amir Khan (ASD, Pakistan) and Prof. Xiaolin Wei

496 (University of Toronto). We thank Dr. Gary F. Lewis from Toronto General Hospital, and Dr. Bruce B.

497 Strumiger from ECHO Institute, University of New Mexico for their support. We also acknowledge all the
498 health providers, patients, and patient champions who participate in discussions to develop the proposal.

499

500 **Declarations**

501 Ethical approvals and consent to participate: The trial protocol has obtained ethical approval from the
502 Office of Research Ethics at the University of Toronto (Ref: 42337) on 23 March 2022 and the Institutional
503 Review Board of the Association for Social Development based in Pakistan (Ref: IORG0011016 dated 04
504 March 2022).

505

506 Informed consent forms with patients' preference of language (Urdu or English) will be collected before
507 any patient is recruited into the study. The healthcare providers will fully explain the information sheet and
508 consent form to the participant in Urdu or English. Both the participant and the healthcare provider are
509 required to sign the consent form. If the participant is not able to sign due to illiteracy, they can use their
510 thumbprint instead. The healthcare provider will keep the signed informed consent form and leave a copy
511 to the participants for their reference.

512

513 Consent for publication

514 Not applicable.

515

516 Availability of data and materials

517 Not applicable as the protocol doesn't report any results.

518

519 Competing interest statement

520 The authors declared no competing interests.

521 Funding statement

522 The trial is funded by the Canadian Institutes of Health Research (CIHR).

523 References

- 524 1. Basu S, Phillips RS. Primary Care in the COVID-19 Pandemic Improving access to high-
525 quality primary care, accelerating transitions to alternative forms of care delivery, and
526 addressing health disparities. 2021.
- 527 2. WHO. Country Cooperation Strategy [Internet]. 2018 [cited 2022 Jan 3]. Available from:
528 <http://apps.who.int/gho/data/node.cco>
- 529 3. Shafi ST, Shafi T. A survey of hypertension prevalence, awareness, treatment, and control
530 in health screening camps of rural central Punjab, Pakistan. *J Epidemiol Glob Health*
531 [Internet]. 2017 Jun 1 [cited 2022 Jan 3];7(2):135–40. Available from:
532 <https://pubmed.ncbi.nlm.nih.gov/28188121/>
- 533 4. Basit A, Fawwad A, Siddiqui SA, Baqa K. Current management strategies to target the
534 increasing incidence of diabetes within Pakistan. *Diabetes Metab Syndr Obes* [Internet].
535 2019 [cited 2022 Jan 3];12:85. Available from: </pmc/articles/PMC6314051/>
- 536 5. Thornton J. Covid-19: how coronavirus will change the face of general practice forever.
537 *BMJ* [Internet]. 2020 [cited 2022 Jan 3];368(m1279). Available from: [www.rcgp.org.uk/-](http://www.rcgp.org.uk/-/media/Files/Policy/A-Z-)
538 </media/Files/Policy/A-Z->
- 539 6. Roth GA, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and
540 national age-sex-specific mortality for 282 causes of death in 195 countries and
541 territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study
542 2017. *The Lancet* [Internet]. 2018 Nov 10 [cited 2022 Jan 3];392(10159):1736–88.
543 Available from: <http://www.thelancet.com/article/S0140673618322037/fulltext>
- 544 7. Sentongo P, Ssentongo AE, Heilbrunn ES, Ba DM, Chinchilli VM. Association of
545 cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality:
546 A systematic review and meta-analysis. *PLoS One* [Internet]. 2020 Aug 1 [cited 2022 Jan
547 3];15(8):e0238215. Available from:
548 <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0238215>
- 549 8. NCD Countdown 2030 collaborators. NCD Countdown 2030: efficient pathways and
550 strategic investments to accelerate progress towards the Sustainable Development Goal
551 target 3.4 in low-income and middle-income countries. Vol. 399, *The Lancet*. Elsevier
552 B.V.; 2022. p. 1266–78.
- 553 9. Monaco A, Palmer K, Faber NHR, Kohler I, Silva M, Vatland A, et al. Digital Health Tools
554 for Managing Noncommunicable Diseases During and After the COVID-19 Pandemic:
555 Perspectives of Patients and Caregivers. *J Med Internet Res* 2021;23(1):e25652
556 <https://www.jmir.org/2021/1/e25652> [Internet]. 2021 Jan 29 [cited 2022 Jan
557 3];23(1):e25652. Available from: <https://www.jmir.org/2021/1/e25652>
- 558 10. Monaghesh E, Hajizadeh A. The role of telehealth during COVID-19 outbreak: A
559 systematic review based on current evidence. *BMC Public Health* [Internet]. 2020 Aug 1
560 [cited 2022 Jan 3];20(1):1–9. Available from:
561 <https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-020-09301-4>
- 562 11. WHO. COVID-19 significantly impacts health services for noncommunicable diseases
563 [Internet]. The World Health Organization. 2020 [cited 2022 Jan 3]. Available from:
564 [https://www.who.int/news/item/01-06-2020-covid-19-significantly-impacts-health-](https://www.who.int/news/item/01-06-2020-covid-19-significantly-impacts-health-services-for-noncommunicable-diseases)
565 [services-for-noncommunicable-diseases](https://www.who.int/news/item/01-06-2020-covid-19-significantly-impacts-health-services-for-noncommunicable-diseases)



- 566 12. Ledwidge M, Gallagher J, Conlon C, Tallon E, O'Connell E, Dawkins I, et al. Natriuretic
567 peptide-based screening and collaborative care for heart failure: the STOP-HF
568 randomized trial. *JAMA* [Internet]. 2013 Jul 3 [cited 2022 Jan 3];310(1):66–74. Available
569 from: <https://pubmed.ncbi.nlm.nih.gov/23821090/>
- 570 13. Greenhalgh T, Koh GCH, Car J. Covid-19: a remote assessment in primary care. *BMJ*
571 [Internet]. 2020 Mar 25 [cited 2022 Jan 3];368. Available from:
572 <https://pubmed.ncbi.nlm.nih.gov/32213507/>
- 573 14. Anjana RM, Pradeepa R, Deepa M, Jebarani S, Venkatesan U, Parvathi SJ, et al.
574 Acceptability and Utilization of Newer Technologies and Effects on Glycemic Control in
575 Type 2 Diabetes: Lessons Learned from Lockdown. *Diabetes Technol Ther* [Internet].
576 2020 Jul 1 [cited 2022 Jan 3];22(7):527–34. Available from:
577 <https://pubmed.ncbi.nlm.nih.gov/32522031/>
- 578 15. India H, Murthy S, Kamath P, Godinho MA, Gudi N, Jacob A, et al. Digital health
579 innovations for non-communicable disease management during the COVID-19 pandemic:
580 a rapid scoping review. *BMJ Innov* [Internet]. 2022 [cited 2022 Nov 26];0:1–16. Available
581 from: <http://innovations.bmj.com/>
- 582 16. PTA. Telecom Indicators. [Internet]. Pakistan Telecom Authority 2021. 2021 [cited 2022
583 Jan 3]. Available from: <https://www.pta.gov.pk/en/telecom-indicators>
- 584 17. Ilyas F. Sindh Assembly body approves telemedicine bill - Pakistan - [Internet]. *Daw*
585 *News*. 2021 [cited 2022 Oct 18]. Available from: <https://www.dawn.com/news/1653441>
- 586 18. Yusufzai A. Telemedicine initiative gaining popularity in KP - Pakistan - DAWN.COM
587 [Internet]. *Dawn News*. 2018 [cited 2022 Oct 18]. Available from:
588 <https://www.dawn.com/news/1412297>
- 589 19. Khoja S, Durrani H. Improving Health Services in Gilgit Baltistan through Telehealth . In:
590 Abstracts from The American Telemedicine Association Sixteenth Annual International
591 Meeting and Exposition. Tampa, Florida: Mary Ann Liebert, Inc; 2011. p. 47.
- 592 20. Jordanova M, Lievens F. A Century of Telemedicine: Curatio Sine Distantia et Tempora A
593 World Wide Overview-Part IV. 2021.
- 594 21. Syed F, Hassan M, Shehzad A, Koul SS, Arif MA, Dewey RS, et al. The establishment of a
595 telemedicine center during the COVID-19 pandemic at a tertiary care hospital in Pakistan.
596 *Clinical eHealth*. 2021 Jan 1;4:50–3.
- 597 22. Syed SI. Political Economy of Reforms: A Case Study of Telemedicine Project in
598 Sheikhpura, Punjab. *Pakistan Perspectives*. 2021;26(2).
- 599 23. Khan MA, Khan N, Walley JD, Khan SE, Hicks J, Sheikh FI, et al. Enhanced hypertension
600 care through private clinics in Pakistan: a cluster randomised trial. *BJGP Open* [Internet].
601 2019 Apr 1 [cited 2022 Jan 3];3(1). Available from: [/pmc/articles/PMC6480862/](https://pubmed.ncbi.nlm.nih.gov/32522031/)
- 602 24. Khan MA, Walley JD, Khan N, Hicks J, Ahmed M, Khan SE, et al. Effectiveness of an
603 integrated diabetes care package at primary healthcare facilities: a cluster randomised
604 trial in Pakistan. *BJGP Open* [Internet]. 2018 [cited 2022 Jan 3];2(4):1–11. Available from:
605 [/pmc/articles/PMC6348328/](https://pubmed.ncbi.nlm.nih.gov/32522031/)
- 606 25. SPIRIT. Guidance for Clinical Trials Protocols [Internet]. 2013 [cited 2022 Dec 20].
607 Available from: <https://www.spirit-statement.org/>

- 608 26. Craig P, Dieppe Paul, Macintyre S, Michie S, Nazareth I, Petticrew M. Developing and
609 evaluating complex interventions: the new Medical Research Council guidance. *BMJ*
610 [Internet]. 2008 [cited 2022 Sep 21]; Available from: www.mrc.ac.uk/
611 27. Northridge ME, Bopp M, Heinrich KM, Harden SM, Smith ML, Ory MG, et al. RE-AiM in
612 clinical, community, and corporate settings: Perspectives, strategies, and
613 recommendations to enhance Public Health impact. *Front Public Health* [Internet].
614 2018;6:22. Available from: www.frontiersin.org
615 28. Moore GF, Audrey S, Barker M, Bond L, Bonell C, Hardeman W, et al. Process evaluation
616 of complex interventions: Medical Research Council guidance. *BMJ* [Internet]. 2015 Mar
617 19 [cited 2022 Sep 21];350. Available from:
618 <https://www.bmj.com/content/350/bmj.h1258>
619 29. Callen M, Gulzar S, Hasanain A, Rehman Khan A, Khan Y, Mehmood MZ. Improving Public
620 Health Delivery in Punjab, Pakistan: Issues and Opportunities. *The Lahore Journal of*
621 *Economics*. 2013;18(SE):249–69.
622 30. Moulton L h. Covariate-based constrained randomization of group-randomized trials. *Clin*
623 *Trials* [Internet]. 2004 [cited 2022 Oct 27];1(3):297–305. Available from:
624 <https://pubmed.ncbi.nlm.nih.gov/16279255/>
625 31. WHO. Classification of digital health interventions v1.0: a shared language to describe
626 the uses of digital technology for health [Internet]. Institute Repository for Information
627 Sharing. 2018 [cited 2022 Nov 26]. Available from:
628 <https://apps.who.int/iris/handle/10665/260480>
629 32. Haldane V, Ratnapalan S, Perera N, Zhang Z, Ge S, Choi M, et al. Codevelopment of
630 COVID-19 infection prevention and control guidelines in lower-middle-income countries:
631 the “SPRINT” principles. *BMJ Glob Health* [Internet]. 2021 [cited 2022 Jan 3];6:6406.
632 Available from: <http://gh.bmj.com/>
633 33. Otu A, Okuzu O, Effa E, Ebenso B, Ameh S, Nihalani N, et al. Training health workers at
634 scale in Nigeria to fight COVID-19 using the InStrat COVID-19 tutorial app: an e-health
635 interventional study: <https://doi.org/10.1177/20499361211040704> [Internet]. 2021 Aug
636 23 [cited 2022 Jan 3];8:204993612110407. Available from:
637 <https://journals.sagepub.com/doi/full/10.1177/20499361211040704>
638 34. Arora S, Thornton K, Murata G, Deming P, Kalishman S, Dion D, et al. Outcomes of
639 treatment for hepatitis C virus infection by primary care providers. *N Engl J Med*
640 [Internet]. 2011 Jun 9 [cited 2022 Jan 3];364(23):2199–207. Available from:
641 <https://pubmed.ncbi.nlm.nih.gov/21631316/>
642 35. Olsen E, Holzhauser B, Julius S, Kjeldsen SE, Cecilie A, Larstorp K, et al. Cardiovascular
643 outcomes at recommended blood pressure targets in middle-aged and elderly patients
644 with type 2 diabetes mellitus compared to all middle-aged and elderly hypertensive
645 study patients with high cardiovascular risk. *Blood Press* [Internet]. 2021 [cited 2022 Jan
646 5];30(2):90–7. Available from:
647 <https://www.tandfonline.com/action/journalInformation?journalCode=iblo20>
648 36. Chen S, Hou X, Sun Y, Hu G, Zhou X, Xue H, et al. A seven-year study on an integrated
649 hospital-community diabetes management program in Chinese patients with diabetes.
650 *Prim Care Diabetes*. 2018 Jun 1;12(3):231–7.

- 651 37. Taler SJ, Agarwal R, Bakris GL, Flynn JT, Nilsson PM, Rahman M, et al. KDOQI US
652 Commentary on the 2012 KDIGO Clinical Practice Guideline for Management of Blood
653 Pressure in CKD. *Am J Kidney Dis*. 2013;62(2):201–13.
- 654 38. Bakris GL. CON: Blood Pressure Treatment Goal for Patients With Diabetes Should Be
655 <130/80 mm Hg. *The Journal of Clinical Hypertension* [Internet]. 2011 Apr [cited 2022
656 Dec 20];13(4):263. Available from: [/pmc/articles/PMC8672985/](https://pubmed.ncbi.nlm.nih.gov/26724178/)
- 657 39. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood
658 pressure lowering for prevention of cardiovascular disease and death: a systematic
659 review and meta-analysis. *Lancet* [Internet]. 2016 Mar 5 [cited 2022 Nov
660 26];387(10022):957–67. Available from: <https://pubmed.ncbi.nlm.nih.gov/26724178/>
- 661 40. Lee YL, Lim YMF, Law KB, Sivasampu S. Intra-cluster correlation coefficients in primary
662 care patients with type 2 diabetes and hypertension. *Trials* [Internet]. 2020 Jun 16 [cited
663 2022 Jan 3];21(1):1–10. Available from:
664 <https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04349-4>
- 665 41. Lee YL, Lim YMF, Law KB, Sivasampu S. Erratum: Intra-cluster correlation coefficients in
666 primary care patients with type 2 diabetes and hypertension (*Trials* (2020) 21 (530) DOI:
667 10.1186/s13063-020-04349-4). *Trials* [Internet]. 2020 Sep 10 [cited 2022 Jan 3];21(1):1–
668 1. Available from: [https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-
669 04715-2](https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04715-2)
- 670 42. Wei X, Walley JD, Zhang Z, Zou G, Gong W, Deng S, et al. Implementation of a
671 comprehensive intervention for patients at high risk of cardiovascular disease in rural
672 China: A pragmatic cluster randomized controlled trial. *PLoS One* [Internet]. 2017 Aug 1
673 [cited 2022 Jan 3];12(8). Available from: <https://pubmed.ncbi.nlm.nih.gov/28813512/>
- 674 43. Gaglio B, Shoup JA, Glasgow RE. The RE-AIM framework: a systematic review of use over
675 time. *Am J Public Health* [Internet]. 2013 Jun [cited 2022 Jan 3];103(6). Available from:
676 <https://pubmed.ncbi.nlm.nih.gov/23597377/>
- 677 44. Wei X, Deng S, Haldane V, Blacklock C, Zhang W, Zhang Z, et al. Understanding factors
678 influencing antibiotic prescribing behaviour in rural China: a qualitative process
679 evaluation of a cluster randomized controlled trial. *J Health Serv Res Policy* [Internet].
680 2020 Apr 1 [cited 2022 Jan 3];25(2):94–103. Available from:
681 <https://pubmed.ncbi.nlm.nih.gov/31986910/>
- 682 45. Wei X, Walley JD, Liang X, Liu F, Zhang X, Li R. Adapting a generic tuberculosis control
683 operational guideline and scaling it up in China: A qualitative case study. *BMC Public
684 Health* [Internet]. 2008 Jul 29 [cited 2022 Jan 3];8(1):1–10. Available from:
685 <https://bmcpublichealth.biomedcentral.com/articles/10.1186/1471-2458-8-260>
- 686 46. Khan MA, Walley JD, Ali S, King R, Khan SE, Khan N, et al. Process evaluation of integrated
687 diabetes management at primary healthcare facilities in Pakistan: a mixed-methods
688 study. *BJGP Open* [Internet]. 2018 [cited 2022 Jan 3];2(4):1–13. Available from:
689 <https://pubmed.ncbi.nlm.nih.gov/30723798/>
- 690 47. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research
691 (COREQ): a 32-item checklist for interviews and focus groups. *Int J Qual Health Care*
692 [Internet]. 2007 Dec [cited 2022 Jan 3];19(6):349–57. Available from:
693 <https://pubmed.ncbi.nlm.nih.gov/17872937/>

- 694 48. Patton MQ. Qualitative research and evaluation methods: Theory and practice. SAGE
695 Publications, Inc. 2015;832.
- 696 49. Diggle P, Heagerty P, Liang K, Zeger S. Analysis of longitudinal data. Vol. Second Edition.
697 Oxford University Press; 2002. 379 p.
- 698 50. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide.
699 Med Decis Making [Internet]. 1993 [cited 2022 Jan 3];13(4):322–38. Available from:
700 <https://pubmed.ncbi.nlm.nih.gov/8246705/>
- 701 51. Bradshaw C, Atkinson S, Doody O. Employing a Qualitative Description Approach in
702 Health Care Research. Glob Qual Nurs Res. 2017 Nov 21;4.
- 703 52. Department for International Development. Pakistan: Integrating NCD care in the
704 primary health care of a developing country - COMDIS-HSDCOMDIS-HSD [Internet]. 2014
705 [cited 2022 Sep 25]. Available from: [https://comdis-hsd.leeds.ac.uk/resource/pakistan-](https://comdis-hsd.leeds.ac.uk/resource/pakistan-integrating-ncd-care-primary-health-care-developing-country/)
706 [integrating-ncd-care-primary-health-care-developing-country/](https://comdis-hsd.leeds.ac.uk/resource/pakistan-integrating-ncd-care-primary-health-care-developing-country/)
707

Community



Peer support



Patient Champions



Patients connect with the RHC staff through smartphone app, as well as virtual and in-person consultations:

- Receive information on NCD and COVID-19
- Get reminders for medication adherence and healthy lifestyles
- Deal with issues regarding NCDs and access to care
- Participate in quarterly patient-health provider forums

Primary care:
Rural Health
Centre (RHC)



Allied Health Workers at RHC provide care to patients via:

- Initial assessment of NCD and COVID-19 via the Integrated COVID-NCD guideline
- Health education
- Support patients through smartphone app

RHC doctors provide consultations for NCD and COVID-19/flu using the COVID-NCD guideline



Patients required specialist care referred to district hospitals



Training and tele-mentoring through ECHO

Secondary care:
District Hospital



Specialist doctors at district hospital provide secondary care, training and tele-mentoring

Figure 1

STUDY PERIOD (MONTHS)

medRxiv preprint doi: <https://doi.org/10.1101/2023.02.17.23285113>; this version posted February 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	
Preparatory phase																									
Study Design, Ethics approval	█	█	█																						
Context Analysis, Smartphone app development				█	█	█																			
Pilot							█	█	█																
Intervention phase																									
Enrolment										█	█														
Intervention												█	█	█	█	█	█	█	█	█	█				
Assessments Phase																									
Process Evaluations																		█	█	█	█	█	█		
Outcome Evaluation																							█	█	
Cost Effective Evaluation																							█	█	
Knowledge Dissemination																							█	█	█
Final Report																									█

Figure 2